Experienced in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED)

Tania Kumpfel

Großhaderner Str. 9, 
Planegg, BY, DE 
Experienced in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED)
Großhaderner Str. 9, 
Planegg, BY, DE 
OverviewLocationsClinical Research

Overview

Tania Kumpfel practices in Planegg, Germany. Ms. Kumpfel is rated as an Experienced expert by MediFind in the treatment of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED). Her top areas of expertise are Optic Neuritis, Multiple Sclerosis (MS), Transverse Myelitis, and Neuromyelitis Optica.

Her clinical research consists of co-authoring 239 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED).

Gender
Female

Locations

Großhaderner Str. 9, Planegg, BY 82152, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Enrollment Status: Terminated
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Enrollment Status: Terminated
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

239 Total Publications

Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis.
Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kumpfel's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 28 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile